The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

SIR: The role of GABA in catatonia has been identified. However, while hypoactivity at GABA A receptor may cause catatonia, increased activity at GABA B may worsen catatonia. 1 We report a patient who suffered from benzodiazepine withdrawal catatonia that could have been worsened by baclofen.

A 61-year-old man was treated for anxiety disorder without depressive features with diazepam 5 mg po TID. The patient was also on baclofen 20 mg po TID for cervicalgia.

The patient complained of chest pain and was admitted to the telemetry unit for observation. His stay was complicated secondary to refusal of medications, and he consequently suffered benzodiazepine withdrawal delirium accompanied by delusions of being poisoned. Laboratory studies including CBC and chemistry were within normal limits, but vital signs indicated mild autonomic elevations (pulse 110, normal sinus rhythm, blood pressure 165/116) consistent with benzodiazepine withdrawal delirium.

A psychiatric consultant noted the presence of catatonic signs including posturing, rigidity, waxy flexibility, negativism, and withdrawal as defined by the refusal of food and oral medications. The Bush-Francis Catatonia Rating Scale score was 20 indicative of moderately severe catatonia. 2

The patient was given an initial dose of lorazepam at 1 mg IV with resolution of his immobility after approximately 1 hour at which time he appeared more agitated with verbal yelling. The patient received haloperidol and ziprasidone during the initial 3 day period to control verbal and physical agitation with mild improvement in overall catatonic signs, but with frequent switching from a psychomotor retarded state to an excited catatonic state. Lorazepam dosed from 3 to 6 mg IV daily was continued during this period to address his benzodiazepine withdrawal delirium as well. Catatonia improved gradually (BFCRS=4), and by the seventh day, the patient showed improvements in orientation, but amnesia to recent events since his illness onset. 2

He was seen 1 month later as an outpatient. The patient been discharged on diazepam 5 mg TID but baclofen was not restarted. Four months after this episode he was readmitted for an exacerbation of congestive heart failure. Diazepam was tapered from 5 mg TID to 2.5 mg TID without the return of catatonia or psychosis.

This patient’s catatonic presentation appeared mostly likely secondary to benzodiazepine withdrawal delirium and a precipitous decline in GABA A activity after his refusal of po medications. 3 However, the presence of catatonia in this case is interesting because baclofen increases the activity of the GABA B receptor. In this case we found that the addition of baclofen may have upset the balance between GABA A and GABA B activity leading to catatonia that required prolonged treatment with lorazepam, a GABA A promoter for resolution. 4 We feel that this case may illustrate a potentially minor but clinically significant procatatonic role for GABA B activity. 1 , 5

University of Cincinnati, and Chillicothe VA Medical Center, Chillicothe, Ohio
University of Cincinnati, Ohio
University of Cincinnati, Ohio
Case Western Reserve University, Cleveland, Ohio
Duke University Medical Center, Durham, N.C.
References

1 . Lauterbach E C: Catatonia-like events after valproic acid with risperidone and sertraline. NNBN 1998; 11:157–163Google Scholar

2 . Bush G, Fink M, Petrides, et al. Catatonia I: Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129–136Google Scholar

3 . Rosebush PI, Mazurek MF: Catatonia after benzodiazepine withdrawal. J Clin Psychopharmacol 1996; 16:315–319Google Scholar

4 . Northoff G: What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555–604Google Scholar

5 . Carroll BT: The GABAa versus GABAb hypothesis of catatonia (letter). Movement Disord 1999; 14:702Google Scholar